Lv71
4173 积分 2021-08-09 加入
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
26天前
已完结
A first-in-class pulsatile FXR agonist for bile-acid-related liver diseases
27天前
已完结
From KRAS G12D to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design
1个月前
已完结
Target identification and assessment in the era of AI
1个月前
已完结
Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Inhibitors of CDK8 for the Treatment of Cancer
1个月前
已完结
Discovery of a Novel Macrocyclic Noncovalent CDK7 Inhibitor for Cancer Therapy
1个月前
已完结
Multimodal clocks of human aging
2个月前
已完结
Recent advances in the discovery of PKMYT1-targeting drugs: a patent review (2021–2025)
2个月前
已完结
Discovery of Novel Inhibitors for WD Repeat‐Containing Protein 5 (WDR5)‐MYC Protein–Protein Interaction
2个月前
已完结
Structure–Activity and Structure–Degradation Relationship Studies of 2-Amino-6-(benzimidazol-2-ylmethyl)-N9-heteroarylpurines as Potent and Selective CDK12/13 Inhibitors and Cyclin K Degraders
2个月前
已完结
皖公网安备34019202002308
